The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Open accessAbstract
PURPOSE: The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo for patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall survival (OS) and other secondary end points. PATIENTS AND METHODS: Patients with a deleterious or suspected deleterious germline BRCA mutation whose disease had not progressed after ≥ 16 weeks of first-line platinum-based chemotherapy were randomly assigned 3:2 to active maintenance olaparib (300 mg twice daily) or placebo. The primary end point was PFS; secondary end points included OS, time to second disease progression or death, time to first and second subsequent cancer therapies or death, time to discontinuation of study treatment or death, and safety and tolerability. RESULTS: In total, 154 patients were randomly assigned (olaparib, n = 92; placebo, n = 62). No statistically significant OS benefit was observed (median 19.0 v 19.2 months; hazard ratio [HR], 0.83; 95% CI, 0.56 to 1.22; P = .3487). Kaplan-Meier OS curves separated at approximately 24 months, and the estimated 3-year survival after random assignment was 33.9% versus 17.8%, respectively. Median time to first subsequent cancer therapy or death (HR, 0.44; 95% CI, 0.30 to 0.66; P < .0001), time to second subsequent cancer therapy or death (HR, 0.61; 95% CI, 0.42 to 0.89; P = .0111), and time to discontinuation of study treatment or death (HR, 0.43; 95% CI, 0.29 to 0.63; P < .0001) significantly favored olaparib. The HR for second disease progression or death favored olaparib without reaching statistical significance (HR, 0.66; 95% CI, 0.43 to 1.02; P = .0613). Olaparib was well tolerated with no new safety signals. CONCLUSION: Although no statistically significant OS benefit was observed, the HR numerically favored olaparib, which also conferred clinically meaningful benefits including increased time off chemotherapy and long-term survival in a subset of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“longer follow up data did not demonstrate a similar improvement in overall survival (OS) compared to patients who received placebo alone following platinum-based therapy88.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Self-citationEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,893
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,602
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ducreux, M. P., Cunha, A. S., Caramella, C., Hollebecque, A., Burtin, P. C., Goèré, D., Seufferlein, T. T. W., Haustermans, K. M., Laethem, J. V., Conroy, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv295 · Cited by 1,309
Self-citationPourshams, A., Sepanlou, S. G., Ikuta, K. S., Bisignano, C., Safiri, S., Roshandel, G., Sharif, M., Khatibian, M., Fitzmaurice, C., Nixon, M. R., et al. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30347-4 · Cited by 666
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648
Lin, K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I. L., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 449
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch–Shimon, S., Kaufman, B., Gershoni‐Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 442
Self-citationO'Reilly, E. M., Lee, J. W., Zalupski, M. M., Capanu, M., Park, J., Golan, T., Tahover, E., Lowery, M. A., Chou, J. F., Sahai, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02931 · Cited by 420
Self-citationGermline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Zhu, H., Wei, M., Xu, J., Hua, J., Chen, L., Meng, Q., Zhang, Y., Liu, J., Zhang, B., Yu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01167-9 · Cited by 263
Reiss, K. A., Mick, R., O’Hara, M. H., Teitelbaum, U. R., Karasic, T. B., Schneider, C. J., Cowden, S., Southwell, T., Romeo, J., Izgur, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00003 · Cited by 258
Walsh, C. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.017 · Cited by 254
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
Friedenson, B. (2005) · PubMed Central · Cited by 218
Wattenberg, M. M., Asch, D., Yu, S., O'Dwyer, P. J., Domchek, S. M., Nathanson, K. L., Rosen, M. A., Beatty, G. L., Siegelman, E. S., & Reiss, K. A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0582-7 · Cited by 211
PARP Inhibition in Cancer: An Update on Clinical Development
Sachdev, E., Tabatabai, R., Roy, V. Y., Rimel, B. J., & Mita, M. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00680-2 · Cited by 190
Oh, M., Alkhushaym, N., Fallatah, S., Althagafi, A. A., Aljadeed, R., Alsowaida, Y. S., Jeter, J., Martin, J. R., Babiker, H. M., McBride, A., et al. (2019) · The Prostate · doi:10.1002/pros.23795 · Cited by 151
Genetic predisposition to pancreatic cancer
Ghiorzo, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10778 · Cited by 109
Matulonis, U. A., Oza, A. M., Ho, T. W., & Ledermann, J. A. (2014) · Cancer · doi:10.1002/cncr.29082 · Cited by 86
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
Gogineni, V., Morand, S. M., Staats, H., Royfman, R., Devanaboyina, M., Einloth, K. R., Dever, D., Stanbery, L., Aaron, P. A., Manning, L., et al. (2020) · Journal of Cancer · doi:10.7150/jca.49406 · Cited by 78
Golan, T., Kindler, H. L., Park, J. O., Reni, M., Macarulla, T. M., Hammel, P. R., Cutsem, E. V., Arnold, D., Hochhauser, D., McGuinness, D. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01890 · Cited by 74
Self-citationPasalic, D., McGinnis, G. J., Fuller, C. D., Grossberg, A. J., Verma, V., Mainwaring, W., Miller, A. B., Lin, T. A., Jethanandani, A., Espinoza, A. F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.015 · Cited by 64
Hammel, P. R., Kindler, H. L., Reni, M., Cutsem, E. V., Macarulla, T. M., Hall, C. M., Park, J. O., Hochhauser, D., Arnold, D., Oh, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz406 · Cited by 44
Self-citationSohal, D. P. S., Mangu, P. B., & Laheru, D. A. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.017368 · Cited by 30
Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Marco, M. D., Rodriquenz, M. G., Centonze, F., Rapposelli, I. G., Giordano, G., Vita, F. D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100032 · Cited by 29
Self-citationTan, P. S., Bilger, M., Lopes, G. D. L., Jr., Acharyya, S., & Haaland, B. A. (2017) · Cancer Medicine · doi:10.1002/cam4.1101 · Cited by 24
Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
Reverdy, T., Sajous, C., Péron, J., Gléhen, O., Bakrin, N., Gertych, W., Lopez, J., You, B., & Freyer, G. (2020) · Cancers · doi:10.3390/cancers12092414 · Cited by 19
Hammel, P. R., Vitellius, C., Boisteau, É., Wisniewski, M., Colle, E., Hilmi, M., d’Engremont, C., Granier, S., Turpin, A., de Mestier, L., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937949 · Cited by 16
Self-citationMartín-Richard, M., & Tobeña, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030470 · Cited by 5
Flagged first, then by citations
Research works printed but not linked: 1
- Friedenson B, 2005, MedGenMed, 7, 60
Cited by
Sorted by citations
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T. T. W., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 601
Therapeutic developments in pancreatic cancer
Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 438
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 468
Molecular tumour boards — current and future considerations for precision oncology
Tsimberidou, A. M., Kahle, M., Vo, H. H., Baysal, M. A., Johnson, A. M., & Meric‐Bernstam, F. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00824-4 · Cited by 145
Metadata
- Authors
- Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E. M., Bordia, S., McGuinness, D., Cui, K., Locker, G. Y., & Golan, T.
- Affiliations
- University of Chicago (US)
- Université Paris-Saclay (FR)
- IRCCS Ospedale San Raffaele (IT)
- University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium
- Vall d'Hebron Hospital Universitari (ES)
- Fox Chase Cancer Center (US)
- Samsung Medical Center (KR)
- University College London (GB)
- Asklepios Klinik Altona (DE)
- Seoul National University (KR)
- St Josef-Hospital, Ruhr University Bochum, Bochum, Germany
- Università Cattolica del Sacro Cuore (IT)
- TUM Klinikum (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Tel Aviv University (IL)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2022-12-01
- Volume
- 40
- Issue
- 34
- Pages
- 3929-3939
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC10476841
- OpenAlex
- W4285386328
- Cited by
- 244
- References
- 39
- Citations by year
- 2026: 60 · 2025: 68 · 2024: 59 · 2023: 48 · 2022: 9
- FWCI
- 19.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-30)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- American Society of Clinical Oncology
- Alnylam Pharmaceuticals
- Celgene
- FibroGen
- Array BioPharma
- Boston Scientific Corporation
- Merck KGaA
- Taiho Pharmaceutical
- Exelixis
- Novocure
- Les Laboratories Pierre Fabre
- Halozyme
- Mylan
- Constellation Pharmaceuticals
- BeiGene
- Incyte
- MacroGenics
- Eisai
- Astellas Pharma
- European Society for Medical Oncology
- Servier
- Swedish Orphan Biovitrum
- Ipsen
- Sirtex Medical
- Aptitude Health
- National Institutes of Health (CA008748)
- Genentech
- EMD Serono
- Chugai Pharmaceutical
- National Cancer Institute (CA008748, P30- 17 CA008748, P30CA008748)
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, maintenance therapy, germline BRCA mutation, metastatic pancreatic adenocarcinoma, PARP inhibitors, overall survival, progression-free survival, platinum-based chemotherapy, secondary malignancies, PARP inhibitor resistance, treatment discontinuation, safety and tolerability
- MeSH terms
- Adenocarcinoma, Female, Germ Cells, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Pancreatic Neoplasms, Phthalazines, Piperazines, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
